Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance

Figure 1

Pharmacological inhibition of ABCG2 modulates the potency of SN-38, but not FL118. A and B, Western blot analysis of ABCG2 protein expression in HCT116 colon cancer cells, drug-resistant HCT116 sub-lines (A), and H460 and EKVX NSCLC cells (B). C and E, dose-response curves in the presence and absence of 1 μM Ko143, an ABCG2 inhibitor, after 72 hour treatments in HCT116 sub-lines (C) and NSCLC cell lines (E). D and F, dose-response curves in the presence and absence of 1 μM Ko143 after 72-hour treatments in HCT116 sub-lines (D) and NSCLC cell lines (F). Viability for each dose was determined using a ViCELL XR cell viability analyzer and normalized to that of DMSO control. Error bars = SEM, n = 3 independent experiments.

Back to article page

Molecular Cancer

ISSN: 1476-4598